Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 6/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 8/20 | 0.46 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29857829 | 0.83 | CHEK2 (0.53) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL26917180 | 0.83 | CHEK2 (0.53) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL12489152 | 0.82 | CHEK2 (0.71) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL26917158 | 0.81 | CHEK2 (0.54) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL29973001 | 0.80 | MAP4K4 (0.56) | CHEK2FYNMAP4K4USP7KDM4E | |
| SCHEMBL2558901 | 0.80 | CHEK2 (0.53) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL3543470 | 0.80 | MAP4K4 (0.59) | CHEK2FYNMAP4K4USP7 | |
| SCHEMBL1869408 | 0.78 | FEN1 (0.55) | CHEK2MAP4K4USP7 | |
| SCHEMBL16973171 | 0.77 | USP7 (0.48) | FYNMAP4K4USP7VRK1 | |
| SCHEMBL31722154 | 0.77 | TAAR1 (0.55) | CHEK2TAAR1MAP4K4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | CHEK2 3885/4885FYN 4684/4885TAAR1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.